ICON Physics: General Overview Martin Köhler and ICON team ICON physics.
ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010
description
Transcript of ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010
![Page 1: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/1.jpg)
ICON plc28th Annual J.P. Morgan Healthcare ConferenceJanuary 2010
![Page 2: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/2.jpg)
Forward Looking Statements
Certain statements contained herein including, without limitation, statements
containing the words “believes,” “anticipates,” “intends,” “expects” and words of
similar import, constitute forward-looking statements concerning the Company's
operations, performance, financial condition and prospects. Because such
statements involve known and unknown risks and uncertainties, actual results may
differ materially from those expressed or implied by such forward-looking statements.
Given these uncertainties, prospective investors are cautioned not to place undue
reliance on such forward-looking statements. The Company undertakes no obligation
to publicly update or revise any forward-looking statements, whether as a result of
new information, future events or otherwise.
This presentation includes selected non-GAAP financial measures. For a presentation
of the most directly comparable GAAP financial measures, please refer to the Quarter
3 2009 press release consolidated income statement headed Consolidated Income
Statements (Unaudited) (US GAAP)
![Page 3: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/3.jpg)
Global Service Offering
![Page 4: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/4.jpg)
Global Full Service Clinical Development
![Page 5: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/5.jpg)
ICONs Global Footprint
Operating from 68 offices in 38 Countries
![Page 6: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/6.jpg)
ICON Plc Staff Growth 1990 - Today
![Page 7: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/7.jpg)
ICON Plc – Staff Educational Qualifications
![Page 8: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/8.jpg)
Drugs in Development by Indication (#compounds)
ICON Backlog by Indication (Revenue)
Drugs in Development by Indication
Source – R&D Directions 9th Annual Report
![Page 9: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/9.jpg)
ICON Phase II-IV Clinical Research
![Page 10: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/10.jpg)
• Full range of Trial Management Services
• >5000 staff working on circa 400 studies with circa 100,000 patients in over 10,000 sites.
ICON Phase II-IV Clinical Research
![Page 11: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/11.jpg)
• Electronic Data Capture (EDC)• Medidata Rave/Phase Forward/ Oracle Clinical RDC / Sponsor
systems• Deployed on c.280 current studies.• 2009 c.160 wins v’s 2005 c.17 wins
• Interactive voice response systems (IVRS)• Patient enrolment, randomisation and management in 850 projects
over 50,000 sites.
Technology in Trial Management
![Page 12: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/12.jpg)
ICON Laboratories
![Page 13: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/13.jpg)
• Capabilities in:• Bio analytical Lab• Bio-marker Lab• Global Central Lab
• Global Lab footprint in key global regions, including the US, UK, Singapore, India and Ireland.
• All ICON laboratories are either GCP or GLP as well as CAP accredited.
• Our BA labs have over 1,500 assays developed in support of over 2500 studies.
ICON Laboratories
![Page 14: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/14.jpg)
ICON Early Phase Testing
![Page 15: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/15.jpg)
• Capacity in excess of 200 beds in the US and UK
• ICON is collaborating with the Central Manchester University Hospitals Foundation to develop a purpose-built translational medicine facility which will be open in 2010.
ICON Early Phase Testing
![Page 16: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/16.jpg)
ICON Medical Imaging
![Page 17: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/17.jpg)
• Market Leading positions in Oncology and CEC based on own proprietary Imaging Management Platform
• Provides world class solutions in the development of imaging biomarkers that support drug development
• Over 100 FDA submissions
ICON Medical Imaging
![Page 18: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/18.jpg)
DOCS (Contract Staffing)
![Page 19: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/19.jpg)
Core Services:
• Functional Resourcing
• Flexible Resourcing Services
• Permanent Recruitment Support
• Training & Development Programs
DOCS (Contract Staffing)
![Page 20: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/20.jpg)
Market Environment
![Page 21: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/21.jpg)
Opportunities…. but also Risks
![Page 22: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/22.jpg)
No of Compounds in Development
* Source :Pharmaprojects
![Page 23: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/23.jpg)
Each 3% Increase in Outsourcing Penetration Drives a 9% Increase in the CRO Market
$26
$74 $74
$36$36$24
R&DSpend
CROMarket
R&DSpend
CROMarket
Bil
lio
ns
Development
Research
Market Penetration
32.4%
Market Penetration
35.4%
9%
![Page 24: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/24.jpg)
Total Biotech Funding ($ Millions)
* Source :Burrell and Co
![Page 25: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/25.jpg)
CRO Market Size 1996 – 2012 (E)
![Page 26: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/26.jpg)
ICON in this Market Environment
![Page 27: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/27.jpg)
New Business Wins and Net Book to Bill Ratio (NB:B)
Net Business Wins
ICLR NB:B (12 Mth Avg.)
Peer NB:B (12 Mth Avg.)
Gross Business Wins Source: Jefferies & Co.
![Page 28: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/28.jpg)
Analysis of Backlog by client type Q3 09
![Page 29: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/29.jpg)
Total Backlog Level ($ Millions)
+6% YoY
![Page 30: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/30.jpg)
Value of backlog forecast to be earned in next 4 quarters
Coverage of next 4 quarters from Backlog
![Page 31: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/31.jpg)
Opportunities…. but also Risks
Strategy
![Page 32: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/32.jpg)
• Build Deep Strategic Relationships
• Create Stronger differentiation across our services
• Retain a flexible business model to respond to
differing client outsourcing strategies
• Build scale in early phase development
• Build scale in post approval business (Phase IV)
• Enter new/grow position in selected markets
ICON’s Strategy
![Page 33: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/33.jpg)
Quality
![Page 34: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/34.jpg)
Quality and Delivery remains our Key Focus.
![Page 35: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/35.jpg)
35
2007 20082009
(to End Sept)
Regulatory Audits 3 3 9
ICON Internal Audits 863 870 836
Client & ISO Audits 255 219 194
Total 1121 1092 1039
We live Quality internally
![Page 36: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/36.jpg)
Financial Performance
![Page 37: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/37.jpg)
CAGR 28%
Net Revenue CAGR of 28% since 2005
* Guidance range issued October 21st 2009
Mill
ions
![Page 38: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/38.jpg)
EBITDA Margin Progression
![Page 39: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/39.jpg)
EBIT Margin Progression
(9 Mths to Sept.)
![Page 40: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/40.jpg)
CAGR 37%
Earnings Per Share Growth
* Guidance range issued October 21st 2009
![Page 41: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/41.jpg)
FCF
Free Cash Flow
* Estimate assumes DSO of approx 60 days. Historic periods FCF exclude Dublin Campus construction costs
![Page 42: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/42.jpg)
Return on Equity
![Page 43: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/43.jpg)
Summary Balance Sheet and Cash Flow($ millions)
9 Mths endedSept 31, 09
Full Year endedDec 31, 08
Cash $173.0 $101.1
Debt $28.0 $105.4
Net Cash/Debt $145.0 ($4.3)
Total assets $922.1 $867.3
Total Liabilities $381.3 $410.9
Shareholder’s equity $540.8 $456.4
Cashflow from operations $198.4 $81.3
Capital expenditures $26.0 $67.9
![Page 44: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/44.jpg)
ICON
S&P 500 Nasdaq Composite
ICON Plc Historic Share Price Performane
![Page 45: ICON plc 28th Annual J.P. Morgan Healthcare Conference January 2010](https://reader034.fdocuments.net/reader034/viewer/2022042608/568153f2550346895dc1f48c/html5/thumbnails/45.jpg)
• Top Global Clinical CRO - #4
• Deep customer relationships
• Quality of staff
• Experienced Management team
• Excellent Reputation
• Solid market fundamentals
• Outstanding record of growth
• Strong balance sheet
Investment Case Summary